immucell8k.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: December 08, 2011
(Date of earliest event reported)
 
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
 
DE
(State or other jurisdiction
of incorporation)
001-12934
(Commission File Number)
01-0382980
(IRS Employer
Identification Number)
 
56 Evergreen Drive
Portland, Maine
(Address of principal executive offices)
  
04103
(Zip Code)
 
207-878-2770
(Registrant's telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 8.01. Other Events
 
ImmuCell Corporation (the “Company”) issued a press release regarding its Mast Out® product offering as presented at the World Animal Health Congress in Kansas City, MO.  on December 8, 2011.
 
Item 9.01. Financial Statements and Exhibits
 
         (c) Exhibits
 
          99.1 Press Release of ImmuCell Corporation, dated December 8, 2011
          99.2 White Paper: Treating Mastitis Without a Loss of Milk Revenue
 
SIGNATURE
 
      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Dated: December 8, 2011
 IMMUCELL CORPORATION
 
 
  By:  /s/ Michael F. Brigham                    
         Michael F. Brigham
         President and CEO
 

 
                                                 Exhibit Index  
   Exhibit No.    Description  
       
  99.1  Press Release of ImmuCell Corporation dated  
                                       December 08, 2011  
       
  99.2  White Paper: Treating Mastitis Without a Loss of  
                                       Milk Revenue